Proviron: The SHBG Binder — Educational Reference
Last updated: March 2026
Mesterolone (Proviron) is a unique oral DHT derivative — not 17α-alkylated, relatively liver-mild, weakly anabolic, and used primarily for its SHBG-binding anti-estrogenic effects and free testosterone enhancement. Used medically for male hypogonadism in Europe. This reference covers its pharmacology, mechanisms, and harm reduction context.
(vs testosterone = 100:100)
Oral (not 17α-alkylated)
Twice-daily dosing common
📋 On this page
How Mesterolone Works
Proviron's value is not in direct anabolism — it's in what it does to the hormonal environment around it. By binding SHBG and competing with aromatization, it acts as a hormonal adjunct rather than a primary anabolic.
Mesterolone has extremely high binding affinity for sex hormone-binding globulin (SHBG) — comparable to DHT. By occupying SHBG binding sites, it displaces testosterone, increasing the free (unbound, bioavailable) fraction. In hypogonadal men with high SHBG, this can meaningfully increase free testosterone bioavailability without changing total testosterone levels.
Mesterolone has weak competitive aromatase inhibitory activity — it can partially compete with testosterone at the aromatase enzyme, reducing estradiol conversion. This effect is modest compared to dedicated AIs (anastrozole, exemestane) but contributes to its overall anti-estrogenic profile when combined with its SHBG displacement mechanism.
Unlike most oral AAS, mesterolone achieves oral bioavailability via a 1α-methyl group rather than 17α-alkylation. This dramatically reduces hepatic stress. Liver enzyme elevation does occur at high doses or prolonged use, but the hepatotoxic risk is significantly lower than Dianabol, Anavar, or Winstrol. This makes it uniquely liver-friendly among oral androgens.
Mesterolone has a reasonable anabolic ratio on paper (~100–150) but poor real-world anabolic effect due to very high SHBG affinity — it binds SHBG more than it binds androgen receptors in muscle tissue. It is rapidly inactivated in muscle. Its primary clinical use was male hypogonadism and fertility enhancement (it maintains spermatogenesis unlike supraphysiological AAS).
What Clinical Research Shows
Data from hypogonadism trials, fertility studies, and pharmacological research on mesterolone.
Side Effects & Risks
Key Takeaways
- Not 17α-alkylated — significantly less hepatotoxic than most oral AAS
- Strong SHBG binding increases free testosterone fraction
- Weak anti-estrogenic effect via SHBG displacement + mild AI activity
- 12-hour half-life — twice daily dosing
- Weakly anabolic on its own — primarily used as a stack adjunct
- Used medically for male hypogonadism and some fertility protocols in Europe
- Still suppresses HPTA (though less than most AAS) — PCT may be needed
- Optimal dosing for SHBG reduction in different individual contexts
- Whether anti-estrogenic effect is clinically meaningful vs dedicated AIs
- Long-term prostate effects (DHT derivative — BPH concern)
- Interaction effects in complex stacks poorly characterized
- Whether it provides meaningful anabolic benefit at any dose
🛒 Monitoring Supplies
Even with lower liver toxicity risk, bloodwork is essential harm reduction for any androgen use.
Related Resources
Want the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
Get the Guide →
This page is for educational and harm reduction purposes only. It is not medical advice. Mesterolone (Proviron) is a Schedule III controlled substance in the United States. While it has medical applications in some European countries, it is not FDA-approved for use in the US. It is banned by WADA and all major sports organizations. Use carries health risks including androgenic effects, HPTA suppression, and cardiovascular changes. Consult a qualified physician before any decisions regarding hormone use. HighPeptides does not endorse or encourage the use of controlled substances.